Xiao Zhang

Xiao Zhang

Auto-generated profile, based on publicly available information

Xiao Zhang

Department of Rheumatology, Zhongshan Hospital, Fudan University , Shanghai

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in Rheumatology
Verified
Journal Article
Closed access
PDF file
XZXiao Zhang
Xiao Zhang
SZShuang Zhou
Shuang Zhou
CWChanyuan Wu
Chanyuan Wu
MLMengtao Li
Mengtao Li
QWQian Wang
Qian Wang
XZXiao-Feng Zeng
Xiao-Feng Zeng
Dear Editor, Anti-melanoma differentiation-associated gene 5 (MDA5)-positive DM is associated with life-threatening rapidly progressive interstitial lung disease (RP-ILD). Even after combination immunosuppressive therapy with high-dose glucocorticoid, CYC and calcineurin inhibitors, more than half of patients died within 3 months of disease onset [ 1, 2]. It has been reported that the serum levels of ferritin, IL-6, IL-8 and IL-10 were higher in the RP-ILD subset than in the non-ILD subset or in the chronic ILD subset [ 3]. Treatment targeting B cells and pro-inflammatory cytokines, such as rituximab, tofacitinib, anakinra or plasmapheresis, has shown promising effectiveness [ 4, 5...

1 March 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
YLYun Liu
Yun Liu
XKXiufang Kong
Xiufang Kong
XZXiao Zhang
Xiao Zhang
ZCZhihong Chen
Zhihong Chen
JWJinghua Wang
Jinghua Wang
LJLindi Jiang
Lindi Jiang
Objective: The objective of this study was to identify novel biomarkers for diagnosis and prediction of active eosinophilic granulomatosis with polyangiitis (EGPA) through data-independent acquisition (DIA) analysis. Methods: Plasma samples from 11 EGPA patients and 10 healthy controls (HCs) were analysed through DIA to identify potential biomarkers. The results were validated in 32 EGPA patients, 24 disease controls (DCs), and 20 HCs using ELISA. The receiver operating characteristic (ROC) curve was used to assess the diagnostic value of candidate biomarkers. Results: Thirty-five differentially expressed proteins (DEPs) (24 upregulated and 11 downregulated) were screened between the EGPA and HC groups. Five proteins, including serine proteinase inhibitor A3 (SERPINA3), alpha-fibrinogen (FGA), alpha-1 acid glycoprotein 1(AGP1), inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3), and serum amyloid A1 (SAA1), were significantly upregulated in EGPA compared with HCs. Apart from SAA1, all proteins were also higher in EGPA patients compared with DCs. Furthermore, a panel of SERPINA3 and SAA1 exhibited potential diagnostic value for EGPA, with an area under the curve (AUC) of 0.953, while a panel of SERPINA3, FGA, AGP1 and ITIH3 showed good discriminative power for differentiating EGPA from DCs, with an AUC of 0.926. Moreover, SERPINA3, FGA and AGP levels were significantly higher in active EGPA and correlated well with disease activity. A combination of SERPINA3 and AGP1 exhibited an excellent AUC of 0.918 for disease activity assessment. Conclusion: SERPINA3, FGA, AGP1, ITIH3 and SAA1 were identified as potential biomarkers for EGPA diagnosis and disease activity assessment. Among them, as a single biomarker, SERPINA3 had the best diagnostic performance.